Clinigen Group (CLIN) Share Price, News & Analysis

Company Overview

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 539,375 shs
• Average Volume: 1.83 million shs
• Market Capitalization: £1.23 billion
• P/E Ratio: 64.69
• Dividend Yield: 0.82%
• Price Target: N/A
• Consensus Rating: N/A

CLIN Stock Analysis - Frequently Asked Questions

How were Clinigen Group's earnings last quarter?

Clinigen Group plc (LON:CLIN) announced its quarterly earnings results on Thursday, September, 17th. The company reported $65.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $63.50 by $2.10.

How do I buy shares of Clinigen Group?

Shares of CLIN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Clinigen Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Albemarle (ALB), Advanced Accelerator Applications (AAAP), First Hawaiian (FHB), GE Aerospace (GE) and Landec (LNDC).

Company Calendar

• Last Earnings: 9/17/2020
• Today: 8/29/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Delivery
• Sub-Industry: Trading
• Current Symbol: LON:CLIN
• CIK: N/A
• Web: www.clinigengroup.com
• Phone: +44-1283-495010
• Fax: N/A
• Employees: 1,000
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 64.69
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 90.77
• Current Ratio: 1.89
• Quick Ratio: 1.48

Sales & Book Value

• Annual Sales: £565.60 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 10.48
• Book Value: GBX 341.90 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 133,367,000
• Free Float: N/A
• Market Cap: £1.23 billion
• Optionable: Not Optionable
• Beta: N/A